Altertoxin I

Altertoxin I (Dihydroalterperylenol; ATX-I) is a quinone mycotoxin with immunosuppressive, mutagenic and anticancer activities. Altertoxin I inhibits LPS (HY-D1056)-mediated NF-κB activation and estrogen-dependent alkaline phosphatase activity. Altertoxin I activates the AhR signaling pathway, induces the expression of CYP 1A1/1A2/1B1 and the enzymatic activity of EROD. Altertoxin I can be used in breast cancer research^[1][2][3]. In Vitro:Altertoxin I (0.001-20 μM; 20 h) suppresses LPS-induced NF-κB pathway activation in THP1-Lucia™ monocytes with significant effects starting at 1 μM, and does not induce cytotoxicity at concentrations up to 20 μM^[1].
Altertoxin I (0.0002-10 μM; 48 h) exerts antiestrogenic effects in Ishikawa cells by suppressing E2-induced alkaline phosphatase activity with significant effects starting at 2 μM, and does not induce cytotoxicity at concentrations up to 10 μM^[1].
Altertoxin I (0.01-5 µM; 24 h) dose-dependently induces EROD enzyme activity in MCF-7 human mammary breast cancer cells, with significant activation starting at 2.5 µM^[2].
Altertoxin I (0.01-5 µM; 24 h) enhances metabolic activity in MCF-7 human mammary breast cancer cells at 5 µM without reducing cell metabolic activity at lower tested concentrations^[2].
Altertoxin I (20 μM; 24 h) exhibits minimal cytotoxicity in A549, HeLa, U2OS, and HepG2 cancer cell lines^[3].